Dexmedetomidine expands monocytic myeloid-derived suppressor cells and promotes tumour metastasis after lung cancer surgery
Open Access
- 11 December 2018
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 16 (1) , 1-13
Abstract
Dexmedetomidine (DEX) has been reported to promote tumour metastases. However the underlying mechanisms remain unclear. The purpose of this study was to investigate whether DEX promotes tumour metastasis by inducing myeloid-derived suppressor cells (MDSC) in the context of surgery. DEX was given to lung cancer patients and its effects on expansion of monocytic MDSC (M-MDSC) were studied in the context of surgery. Spontaneous tumour metastasis was induced in C57BL/6 mice and the effects of DEX on M-MDSC expansion and metastasis formation were assessed. DEX increased CD11b+CD33+HLA-DR–CD14+ M-MDSC in lung cancer patients after thoractomy. DEX-induced M-MDSC, in addition to have immunosuppressive activity, were more efficient in producing VEGF. Expansion of M-MDSC by DEX involved α2-adrenergic receptor. Using an experimental tumour metastasis mouse model, we demonstrated that the numbers of metastases on lung surface and CD11b+Ly6ChighLy6G− M-MDSC during postoperative period were enhanced in DEX-treated mice. Promotion of tumour metastasis by DEX-induced M-MDSC involved VEGF, a key factor for tumour angiogenesis. DEX induces the proliferation of M-MDSC during postoperative period in lung cancer patients and this cell population is qualified with potent proangiogenic ability. Treatment of mice with DEX expands M-MDSC and promotes tumour metastasis through the increasing production of VEGF.Keywords
Funding Information
- National Natural Science Foundation of China (31660257, 81760519, 31360223)
This publication has 44 references indexed in Scilit:
- Dexmedetomidine protects against renal ischemia and reperfusion injury by inhibiting the JAK/STAT signaling activationJournal of Translational Medicine, 2013
- Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cellsBlood, 2011
- Improving Postoperative Immune Status and Resistance to Cancer MetastasisAnnals of Surgery, 2011
- COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor CellsCancer Research, 2011
- The biology of myeloid‐derived suppressor cells: The blessing and the curse of morphological and functional heterogeneityEuropean Journal of Immunology, 2010
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- α2‐Adrenoceptor action on cell proliferation and mammary tumour growth in miceBritish Journal of Pharmacology, 2008
- Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell–suppressive activityBlood, 2008
- Expression of α-AR Subtypes in T Lymphocytes and Role of the α-ARs in Mediating Modulation of T Cell FunctionNeuroimmunomodulation, 2007
- Major Abdominal Surgery Increases Plasma Levels of Vascular Endothelial Growth FactorAnnals of Surgery, 2006